Kashif Latif, MD
Endocrinology · Bartlett, TNNPI 1902913692
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 51.7% of the total. 2025 is the largest year on record at $115,921, 5.2 times the $22,193 reported in 2019.
Across 1,302 payments — averaging $207.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$139K
- Senseonics, Incorporated$26K
- Ascensia Diabetes Care US Inc.$22K
- Mannkind Corporation$20K
- Abbott$20K
- Tandem Diabetes Care, Inc.$8K
- plus $34K from 49 others
Across 1,498 payments — averaging $604.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$266K
- Novo Nordisk AS$169K
- Eli Lilly$163K
- Sanofi US Services Inc.$85K
- Mannkind Corporation$81K
- Senseonics, Incorporated$65K
- plus $76K from 2 others
What the payments were for
- Consulting fees$72,20027%
- Speaking & faculty fees$139,49352%
- Travel & lodging$35,62613%
- Food & beverage$22,1918%
- Education$510%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$144,220
- Eversense$26,180
- AFREZZA$18,748
- BIGFOOT UNITY DIABETES MANAGEMENT SYSTEM$18,700
- t-slim insulin pump$6,600
- EVERSENSE 365 SENSOR KIT (RETAIL)$6,166
- Minimed 770G System$5,025
- InPen$2,500
- Omnipod$1,960
- t:slim X2 insulin pump$1,550
- EVERSENSE E3 SMART TRANSMITTER KIT$506
- EVERSENSE E3 SENSOR KIT - RETAIL$450
- Minimed 670G System$171
- MINIMED 780G$167
- GRAFIX PL$115
- Tirosint$110
- Licart$110
- FLECTOR$110
How this compares
Too few endocrinology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,004 | $1,378,396 |
| MounjaroTirzepatide | 663 | $949,461 |
| JardianceEmpagliflozin | 487 | $575,634 |
| TrulicityDulaglutide | 272 | $456,827 |
| FarxigaDapagliflozin Propanediol | 331 | $348,340 |
| Tresiba Flextouch U-100Insulin Degludec | 430 | $309,157 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 188 | $293,228 |
| Tresiba Flextouch U-200Insulin Degludec | 103 | $114,341 |
| Xigduo XrDapaglifloz Propaned/Metformin | 112 | $107,569 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 99 | $102,258 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $82,697 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $81,792 |
| JanuviaSitagliptin Phosphate | 64 | $51,882 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $51,771 |
| NovologInsulin Aspart | 119 | $50,992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $2,593 | $1,491,8141,159 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $3,434 | $1,475,8711,056 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $723 | $733,749646 claims |
| AstraZenecaFarxiga | $839 | $348,340331 claims |
| MerckJanuvia, Janumet, Janumet Xr | $332 | $97,276100 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $139,322 | $81,79260 claims |
| AbbVieCreon, Synthroid | $1,397 | $59,448291 claims |
| AmgenProlia | $541 | $24,44915 claims |
| BayerKerendia | $625 | $23,14524 claims |
| Mannkind CorporationAfrezza | $20,215 | $19,04811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Bartlett
- Mohammad QureshiCordova$5K
- Manasa VeluruKingsport$1K
- Eduardo Lopez MartinezNashville$0
- Chase HendricksonNashville$0
- Lauren MozingoNashville$0
- Syeda ZaidiNashville$0
- Jennifer HewlettNashville$0
- Alvin PowersNashville$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.